Sumitovant Biopharma to take full ownership of Myovant Sciences for $1.7bn
Sumitovant Biopharma, a subsidiary of Japan-based Sumitomo Pharma (previously Sumitomo Dainippon Pharma), is set to take full ownership of Myovant Sciences, an American publicly-listed biopharma company, in a deal worth $1.7 billion. In this connection, Sumitovant Biopharma will offer a price of $27 per share in cash to acquire the remaining 48% stake that it […]